{"groups":[{"description":"Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22,\n\nOfatumumab and Bortezomib: Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22- in the induction phase Ofatumumab 1000 mg IV on day 1- will receive in the maintenance phase Patients will remain until progression","id":"FG000","title":"Ofatumumab IV,"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"10"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"10"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}